Table of Contents
Executive Summary — 7
SWOT
Analysis — 8
Malaysia Pharmaceuticals And Healthcare
Industry SWOT — 8
Malaysia Political
SWOT — 9
Malaysia Economic SWOT — 10
Malaysia Business Environment SWOT — 11
Pharmaceutical
Business Environment Ratings — 12
Table: Asia Pacific
– Regional Business Environment Rankings For
Q309 — 12
Limits Of Potential
Returns — 13
Risks To Realisation Of
Returns — 13
Malaysia – Market
Summary — 15
Regulatory Regime — 16
Pharmaceutical And Medical Advertising — 17
Recent
Regulatory Developments — 17
Intellectual Property
Regime — 18
Counterfeit
Pharmaceuticals — 20
Compulsory
Licensing — 21
Free Trade
Agreements — 21
Pricing And
Reimbursement — 22
Industry Trends And
Developments — 24
Epidemiology — 24
Table: 10 Leading Causes Of Death In Ministry of Health Hospitals,
2005 — 24
Communicable Disease — 26
Healthcare Sector — 26
Healthcare Sector
Funding — 27
Recent Healthcare Sector
Developments — 28
Medical Tourism — 28
Pharmaceutical Sector — 29
Pharmaceutical
Demand — 30
Domestic Company
Activity — 30
Foreign Company
Activity — 31
Halal Medicine — 32
Traditional Medicine — 33
Biotechnology And
Research — 33
Table: Key Points Of The Malaysian National
Biotechnology Policy — 34
Table: The Benefits Of
Conducting Biotechnology Research In Malaysia — 36
Recent
Biotechnology Developments — 36
Clinical
Trials — 37
Medical Devices — 39
Table: Malaysia – Clinical Diagnostics Market, 2006
(US$mn) — 39
Leading Medical Device
Players — 40
Recent Developments In The Medical Devices
Industry — 42
Industry Forecast
Scenario — 43
Overall Market
Forecast — 43
Table: Malaysia – Drug Expenditure
Indicators, Historical Data and Forecasts — 44
Key Growth
Factors – Industry — 45
Table: Malaysia –
Health Expenditure Indicators, Historical Data and
Forecasts — 46
Key Growth Factors –
Macroeconomic — 47
TABLE: Malaysia – Economic
Activity, 2006 – 2013 — 49
Prescription Market
Forecast — 50
Table: Malaysia – Prescription Market
Indicators, Historical Data And Forecasts (MYRmn unless otherwise
stated) — 52
Patented Market
Forecast — 53
Table: Malaysia – Patented Drug Market
Indicators, Historical Data and Forecasts — 54
Generic
Drug Market Forecast — 55
Table: Malaysia – Generics
Drugs Market Indicators, Historical Data and
Forecasts — 56
OTC Market
Forecast — 57
Table: Malaysia – OTC Drug Market
Indicators, Historical Data and Forecasts (MYRmn unless otherwise
stated) — 58
Pharmaceutical Trade
Forecast — 59
Table: Malaysia – Pharmaceutical Trade
Indicators, Historical Data and Forecasts US$mn) — 60
Other Healthcare Data Forecasts — 60
Table: Malaysia
– Other Healthcare Indicators, Historical Data and
Forecasts — 61
Key Risks To BMI’s Forecast
Scenario — 62
Competitive
Landscape — 63
Company Profiles — 64
Multinational Companies — 64
GlaxoSmithKline
(GSK) — 64
Pfizer — 66
Novartis — 68
Merck & Co — 70
Sanofi-Aventis — 71
Ranbaxy
Malaysia — 72
Eli Lilly Malaysia — 74
Leading Indigenous Manufacturers — 75
Pharmaniaga — 75
Asia Pharmaceutical Products
(APP) — 79
Prime Pharmaceutical — 80
Bumimedic — 81
Hovid — 83
Chemical
Company of Malaysia (CCM) — 86
Kotra
Pharma — 89
YSP Southeast Holding — 91
Country Snapshot: Malaysia Demographic Data — 94
Section
1: Population — 94
Table: Demographic Indicators,
2005-2030 — 94
Table: Rural/Urban Breakdown,
2005-2030 — 95
Section 2: Education And
Healthcare — 95
Table: Education,
2000-2003 — 95
Table: Vital Statistics,
2005-2030 — 95
BMI Forecast
Modelling — 96
How We Generate Our Pharmaceutical Industry
Forecasts — 96
Pharmaceutical Business Environment Ratings
Methodology — 97
Ratings Overview — 97
Table: Pharmaceutical Business Environment Indicators — 98
Weighting — 99
Table: Weighting Of
Components — 99
Sources — 99
| 
View Cart
